KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to $110.6 million.

  • Sarepta Therapeutics' Change in Accured Expenses fell 6223.03% to -$103.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.1 million, marking a year-over-year decrease of 144.47%. This contributed to the annual value of $110.6 million for FY2024, which is 320.70% up from last year.
  • As of FY2024, Sarepta Therapeutics' Change in Accured Expenses stood at $110.6 million, which was up 320.70% from -$50.1 million recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' Change in Accured Expenses registered a high of $147.6 million during FY2022, and its lowest value of -$50.1 million during FY2023.
  • Its 3-year average for Change in Accured Expenses is $69.4 million, with a median of $110.6 million in 2024.
  • In the last 5 years, Sarepta Therapeutics' Change in Accured Expenses soared by 533.44% in 2022 and then plummeted by 133.97% in 2023.
  • Over the past 5 years, Sarepta Therapeutics' Change in Accured Expenses (Yearly) stood at $42.0 million in 2020, then slumped by 44.53% to $23.3 million in 2021, then spiked by 533.44% to $147.6 million in 2022, then plummeted by 133.97% to -$50.1 million in 2023, then surged by 320.70% to $110.6 million in 2024.